Tardive Dyskinesia Treatment Market Size

SkyQuest Technology's Tardive dyskinesia treatment market size, share and forecast Report is based on the analysis of market data and Industry trends impacting the global Tardive Dyskinesia Treatment Market and the revenue of top companies operating in it. Market Size Data and Statistics are based on the comprehensive research by our Team of Analysts and Industry experts.

Tardive Dyskinesia Treatment Market Insights

Global Tardive Dyskinesia Treatment Market size was valued at USD 3.6 billion in 2023 and is poised to grow from USD 3.88 billion in 2024 to USD 7.08 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032). 

Growing incidence of psychiatric disorders, advancements in VMAT2 Inhibitor therapies, regulatory support for accelerated approvals, expansion of healthcare infrastructure, and rising awareness regarding tardive dyskinesia are slated to promote the adoption of tardive dyskinesia treatment.

The increasing global incidence of psychiatric conditions, such as schizophrenia and bipolar disorder, necessitates long-term antipsychotic medication use, a primary cause of tardive dyskinesia. Increasing awareness regarding tardive dyskinesia and accelerated approval of treatments for the same are also supplementing the global tardive dyskinesia treatment market growth. Emerging economies are witnessing significant improvements in healthcare infrastructure, including increased access to neurological and psychiatric care. Pharmaceutical companies are increasingly engaging in strategic partnerships and collaborations to advance tardive dyskinesia treatment research.

On the contrary, high costs of tardive dyskinesia treatment, adverse side effects of current therapies, limited awareness in developing regions, and limited R&D investments due to small patient population are slated to impede the global tardive dyskinesia treatment adoption across the forecast period and beyond.

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Tardive Dyskinesia Treatment Market size was valued at USD 9.75 Billion in 2023 and is poised to grow from USD 10.11 Billion in 2024 to USD 13.52 Billion by 2032, growing at a CAGR of 3.7% during the forecast period (2025-2032).

Tardive dyskinesia treatment providers should focus on investing in R&D to develop new therapeutics and treatments. Working with government organizations and health non-profits can also expand the business scope for market players. Developing treatment with minimal side effects is a key opportunity as per the global tardive dyskinesia treatment market analysis. 'Teva Pharmaceutical Industries Ltd.', 'Neurocrine Biosciences Inc.', 'Medicure Inc.', 'Mylan N.V', 'Dr. Reddy’s Laboratories Ltd.', 'Sun Pharmaceutical Industries Ltd. ', 'Bionpharma', 'Hetero', 'Bausch Health', 'Sanofi', 'Johnson & Johnson Services Inc.', 'GlaxoSmithKline Plc.', 'Lupin Pharmaceuticals Inc.', 'Lilly', 'Novartis AG'

Regulatory agencies, notably the U.S. Food and Drug Administration (FDA), have adopted expedited pathways for TD treatments, recognizing the unmet medical need. Fast-track designations and priority reviews facilitate quicker market entry for promising therapies. This regulatory support incentivizes pharmaceutical companies to invest in TD drug development and favors the global tardive dyskinesia treatment market outlook as well.

Advancements in VMAT2 Inhibitor Therapies: The development and approval of vesicular monoamine transporter 2 (VMAT2) inhibitors, such as valbenazine (Ingrezza) and deutetrabenazine (Austedo), have revolutionized TD treatment. These medications specifically target the underlying mechanisms of TD, offering improved efficacy and safety profiles compared to traditional therapies. The introduction of alternative formulations, like Ingrezza Sprinkle, caters to patients with swallowing difficulties, enhancing treatment adherence. Hence, focusing on advancement of therapies is slated to be a top tardive dyskinesia treatment market trend in the long run.

Why is the Adoption Rate of Tardive Dyskinesia Treatment High in North America?

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Tardive Dyskinesia Treatment Market
Tardive Dyskinesia Treatment Market

Report ID: SQMIG35I2373

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE